Angiogenesis, the formation of new blood vessels, is fundamental to development and post-injury tissue repair. Vascular endothelial growth factor (VEGF)-A guides and enhances endothelial cell migration to initiate angiogenesis. Profilin-1 (Pfn-1) is an actin-binding protein that enhances actin filament formation and cell migration, but stimulus-dependent regulation of Pfn-1 has not been observed. Here, we show that VEGF-A-inducible phosphorylation of Pfn-1 at Tyr 129 is critical for endothelial cell migration and angiogenesis. Chemotactic activation of VEGF receptor kinase-2 (VEGFR2) and Src induces Pfn-1 phosphorylation in the cell leading edge, promoting Pfn-1 binding to actin and actin polymerization. Conditional endothelial knock-in of phosphorylation-deficient Pfn1 Y129F in mice reveals that Pfn-1 phosphorylation is critical for angiogenesis in response to wounding and ischaemic injury, but not for developmental angiogenesis. Thus, VEGFR2/Src-mediated phosphorylation of Pfn-1 bypasses canonical, multistep intracellular signalling events to initiate endothelial cell migration and angiogenesis, and might serve as a selective therapeutic target for anti-angiogenic therapy.
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Immunoblot of endothelial cell lysates with anti-Pfn-1, -Pfn-2 and -GAPDH antibodies (left). Endothelial cells were subjected to a Transwell migration assay with or without VEGF-A in the lower chamber (mean ± s.e.m., three independent experiments; right). (b) Human umbilical vein endothelial cells were transfected with pTandem-Pfn-1-His or vector, and lysates were precipitated with Ni + beads, resolved in SDS-PAGE and stained with GelCode Blue (inset). Phosphorylation sites in the Pfn-1 band were identified by mass spectrometry. The collision-induced dissociation spectrum for P-Tyr-129-containing peptide, CpYEMoASHLR (m/z = 632.0), is shown. The y 7 and y 8 ions exhibit a mass difference consistent with a phosphorylated tyrosine (P-Tyr) at position 129. (c) Confluent, quiescent or subconfluent, migrating bovine aortic endothelial cells were serum-deprived and treated with VEGF-A. Cell lysates were incubated with purified Pfn-1 in buffer containing [γ- 32 P]ATP. Proteins before and after immunoprecipitation (IP) with anti-Pfn-1 antibody were resolved by SDS-PAGE, bands were visualized by autoradiography and quantified by densitometry (mean ± s.e.m., three independent experiments), and immunoblotted (IB) with anti-Pfn-1. (d) VEGF-A-treated endothelial cells were metabolically labelled with [ 32 P]orthophosphoric acid and cell lysates were immunoprecipitated with anti-Pfn-1 antibody. Pfn-1 phosphorylation was visualized by SDS-PAGE and autoradiography, and immunoprecipitated Pfn-1 was detected by immunoblotting. (e) Endothelial cell lysates were immunoprecipitated with anti-Pfn-1 antibody, and immunoblotted with anti-phospho-tyrosine, anti-phospho-serine, anti-phospho-threonine and anti-Pfn-1 antibodies. (f) Multiple sequence alignment of Pfn-1. (g) Phospho-specific antibody was generated by immunizing rabbits with KKCpYEMASHLRR peptide. Serum-deprived bovine aortic endothelial cells were treated with VEGF-A, and lysates were resolved by SDS-PAGE, and immunoblotted with anti-P-Pfn-1-Tyr-129 and anti-Pfn-1 antibodies. (h) Human umbilical vein endothelial cells were transfected with pcDNA vector or pcDNA-Pfn-1-Flag with or without mutations. Cell lysates were immunoprecipitated with anti-Flag antibody, resolved by SDS-PAGE, and immunoblotted with anti-phospho-tyrosine and anti-Pfn-1 antibodies. Uncropped images of blots are shown in Supplementary Fig. S8 .
with 72% coverage were identified. Collision-induced dissociation spectra revealed three phospho-peptides: SSFpY 60 VNGLTLGGQK, TKpS 92 TGGAPTFNVTVTK and CpY 129 EMoASHLR ( Fig. 1b and Supplementary Fig. S2 ); other post-translational modifications, including methylation and acetylation, were not detected. Stimulusinducible Pfn-1 phosphorylation by VEGF-A was confirmed by 32 P-labelling in vitro. Lysates from VEGF-A-treated, subconfluent cells induced robust phosphorylation of purified Pfn-1, whereas lysates from confluent endothelial cells showed only weak labelling activity; Pfn-1 phosphorylation was verified by immunoprecipitation (Fig. 1c) . To confirm the results in vivo, cells were metabolically labelled with [ 32 P]orthophosphate. Basal and VEGF-A-inducible Pfn-1 phosphorylation was substantially greater in subconfluent, migrating cells (Fig. 1d) .
Using phospho-specific antibodies, VEGF-A-inducible Pfn-1 phosphorylation in subconfluent cells was detected primarily on tyrosine (Fig. 1e) . Multiple sequence alignment of Pfn in vertebrate species revealed conservation of Tyr 129, but not Tyr 60, suggesting the former is more likely to exhibit an important regulatory function (Fig. 1f ). Immunoblot analysis with a polyclonal antibody that we generated against a P-Tyr-129-containing Pfn-1 peptide confirmed VEGF-A-inducible phosphorylation of Tyr 129 in migrating endothelial cells (Fig. 1g) . To confirm these results in a cellular context, endothelial cells were transfected with Flag-tagged Pfn-1, stimulated to migrate, and phosphorylation was determined by immunoprecipitation and probing with anti-phospho-tyrosine antibody. Phosphorylation of Y129A and Y129F Pfn-1 mutants was markedly diminished when compared with wild-type protein (Fig. 1h) . Taken together, these data indicate that Tyr 129 is the main VEGF-A-responsive phosphorylation site in Pfn-1.
Pfn-1 phosphorylation at Tyr 129 promotes binding to G-actin and actin polymerization
To explore the function of phosphorylation of Pfn-1 at Tyr 129, binding partners of Flag-tagged Pfn-1 in migrating endothelial cells were determined by mass spectrometry. β-actin was identified as the main Pfn-1 target that preferentially binds the phosphorylatable, wild-type form but not the phosphorylation-defective Y129A mutant (Fig. 2a) . The stimulus-and phosphorylation-dependent interaction between β-actin and Pfn-1 was confirmed by co-immunoprecipitation (Fig. 2b) . Structural and biochemical studies show that Tyr 129 is in the carboxy-terminal α-helix crucial for Pfn-1 binding to actin 23, 24 ( Fig. 2c) . The determination of binding constants by surface plasmon resonance showed that phosphorylation of Pfn-1 (by in vitro incubation of wild-type Pfn-1 with lysate from VEGF-A-activated cells) moderately increased its affinity for β-actin; a similar treatment of the Y129A mutant was ineffective (Fig. 2d) . Phosphorylation might enhance binding to β-actin by facilitating an electrostatic interaction between P-Tyr-129 in Pfn-1 and the nearby Arg 372 in β-actin (Fig. 2c) . Moreover, when compared with the non-phosphorylatable Y129A mutant, phosphorylated Pfn-1 nearly doubled the initial rate of nucleotide exchange on G-actin required for addition to growing actin filaments (Fig. 2e) . To determine the effect of Tyr 129 phosphorylation on actin filament formation, G-actin was induced to polymerize in vitro in the presence of thymosin-β4, barbed-end-free spectrin F-actin seeds, and wild-type or Y129A Pfn-1 pre-treated with lysate from VEGF-A-activated cells 25 . Pfn-1 liberates G-actin from thymosin-β4
and promotes its addition to the barbed end of F-actin 15, 26, 27 . P-Pfn-1 increased the initial rate of actin polymerization substantially when compared with phosphorylation-dead Pfn-1 Y129A (Fig. 2f,g ). Thus, stimulus-inducible phosphorylation of Pfn-1 at Tyr 129 increases its affinity for G-actin, enhances nucleotide exchange on actin, and promotes actin polymerization in vitro.
Several proline-rich proteins and phosphatidylinositol-4,5-bisphosphate (PtdIns(4, 5)P 2 ) are Pfn-1 ligands, and their interaction regulates actin dynamics and cell motility 15, [28] [29] [30] . Coimmunoprecipitation experiments revealed that Pfn-1 phosphorylation does not significantly affect its interaction with proline-rich proteins VASP and N-WASP ( Supplementary Fig. S3a) . Interestingly, the three-dimensional X-ray structure of the Pfn-1-actin-VASP ternary complex reveals that Tyr 129 of Pfn-1 is close to or within the actin-binding site, but on the opposite side of the protein from the domain that binds the poly-l-proline domain of VASP (ref. 31; Supplementary Fig. S3b ). Furthermore, lipid co-sedimentation and filtration binding analyses showed that phosphorylation of Pfn-1 does not influence its binding to PtdIns(4,5)P 2 ( Supplementary Fig. S3c-f ).
Pfn-1 phosphorylation at Tyr 129 is induced by VEGFR2 and Src kinases
We investigated the identity of the kinase responsible for VEGF-Ainduced Pfn-1 phosphorylation, initially focusing on known downstream kinases of VEGFR2, the main receptor kinase for angiogenic signalling by VEGF-A (refs 10,32,33) . The immediate downstream tyrosine kinases of VEGFR2 include focal adhesion kinase (FAK) and Src family members Src, Fyn and Lyn (ref. 34 ). Short interfering RNA (siRNA)-mediated knockdown indicated that only Src contributes to VEGF-A-induced Pfn-1 phosphorylation (Fig. 3a) . Moreover, pharmacological inhibitors of VEGFR2 (indolin and dihydroindole, 5 µM), and a receptor tyrosine kinase inhibitor (PD173074, 5 µM), almost completely inhibited VEGF-A induced Src phosphorylation at Tyr 416, the autophosphorylation site necessary for Src activation, suggesting that VEGF-A induces VEGFR2-dependent Src activation (Fig. 3b) . To examine the possibility that Src is a proximal, that is, direct Pfn-1 kinase, cell lysates were subjected to immunodepletion and used as the kinase source for in vitro phosphorylation. Depletion of Src markedly suppressed Pfn-1 phosphorylation (Fig. 3c) . Remarkably, depletion of VEGFR2 in lysates modestly reduced the level of Pfn-1 phosphorylation as well. Immunoblot analysis with anti-P-Pfn-1-Tyr-129 antibody confirmed site-specific phosphorylation by VEGFR2 and more robust phosphorylation by Src (Fig. 3d) . The kinase domain of VEGF receptor-3 (VEGFR3) that responds primarily to VEGF-C and -D (refs 35,36) , and FAK, showed a low level of activity towards this target. An immunocomplex phosphorylation assay confirmed that VEGFR2-and Src-containing complexes in cell lysates directly phosphorylate Pfn-1 at Tyr 129 (Fig. 3e) .
Direct Pfn-1 phosphorylation by VEGFR2 and its immediate downstream kinase suggests that VEGF-A may bypass intracellular signalling cascades to induce Pfn-1 phosphorylation. Consistent with this idea, pharmacological inhibition of VEGFR2 and receptor tyrosine kinases almost completely suppressed VEGF-A-stimulated Pfn-1 phosphorylation at Tyr 129, whereas inhibitors of PI(3)K (LY294002, 10 µM) and PKC (calphostin C, 2 µM) were ineffective (Fig. 3f) . Moreover, PI(3)K-independence of VEGF-A-induced Pfn-1
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Pfn-1-His V e c t o r V e c t o r V e c t o r phosphorylation was shown by the absence of inhibition by siRNAmediated knockdown of major PI(3)K isoforms implicated in vascular development and angiogenesis, namely, p110α, β, γ and δ (Fig. 3g) . Likewise, expression of constitutively active, myristoylated (myr) Akt-1, a major effector kinase of PI(3)K, did not stimulate Pfn-1 phosphorylation (Fig. 3h) , confirming PI(3)K-independent Pfn-1 phosphorylation by VEGF-A.
Ligand and receptor specificity was shown by the absence of robust Pfn-1 phosphorylation by other growth factors, including the VEGFR1-specific agonist placenta growth factor 37 (PlGF), VEGF-C, epidermal growth factor (EGF), platelet-derived growth factor (PDGF) and sphingosine-1-phosphate (S1P; Fig. 3i,j) . Interestingly, an inhibitory peptide that targets the VEGF-A-binding site of VEGFR1, and knockdown of VEGFR1, inhibited VEGF-A-induced Pfn-1 phosphorylation ( Supplementary Fig. S4a,b) , suggesting that VEGFR1 contributes to Pfn-1 phosphorylation. Although VEGFR1 exhibits in vitro kinase activity directed to Pfn-1 ( Supplementary  Fig. S4c-e) , ectopic expression of VEGFR2, but not VEGFR1, effectively reconstituted VEGF-A-induced Pfn-1 phosphorylation in VEGFRnegative fibroblasts ( Supplementary Fig. S4f,g ). These results are consistent with a role for VEGF-binding activity, but not kinase activity, of VEGFR1 in Pfn-1 phosphorylation. Furthermore, fibroblast expression of VEGFR2 mutated at Tyr 951 in the docking site for T-cell-specific adapter (TSAd) protein 38 , but not at Tyr 1175 in the activation site for PLCγ/PI (3) factors in VEGFR2 activation and Pfn-1 phosphorylation. Together, these findings reveal both VEGFR2 and its downstream Src kinase as proximal, Pfn-1-selective tyrosine kinases.
Pfn-1 phosphorylation at Tyr 129 is spatially restricted to cell leading edge and is required for VEGF-A-stimulated endothelial cell migration
Polarized signals initiating cell motility generally evoke a spatially restricted response 40, 41 . To visualize the spatial distribution of phosphorylated Pfn-1, endothelial cells were induced to migrate towards a VEGF-A gradient in a modified Zigmond chamber. Tyr-129-phosphorylated Pfn-1 preferentially was observed at the leading edge, almost precisely co-localizing with F-actin ( Fig. 4a and Supplementary Fig. S5a,b) . Transfection of cells with pECFP-Pfn-1 and detection by fluorescence analysis showed a small amount of Pfn-1 at the leading edge in most cells with the preponderance localized far behind this region ( Supplementary Fig. S5a ). The spatially restricted phosphorylation of Pfn-1 is probably due to asymmetric activation of VEGFR2 and Src, as indicated by localization of Tyr-951-, Tyr-1175-and Tyr-1214-phosphorylated VEGFR2 and Tyr-416-phosphorylated Src at the cell leading edge (Fig. 4b,c) . To investigate the role of Pfn-1 phosphorylation in VEGF-A-induced endothelial cell migration, endogenous Pfn-1 was depleted by stable expression of lentivirus-driven shRNA targeting the 3 -UTR, and Pfn-1 was restored by transfection with complementary DNA encoding wild-type or mutated mouse Pfn-1 coding sequence (CDS) lacking the 3 -UTR (Fig. 4d) . Depletion of Pfn-1 reduced endothelial cell migration in response to VEGF-A by about 70%. Expression of wild-type Pfn-1 substantially restored motility, but phospho-dead mutants were completely ineffective. Thus, Pfn-1 phosphorylation at Tyr 129 has a critical role in VEGF-A-induced in vitro endothelial cell migration.
Pfn-1 phosphorylation at Tyr 129 is elevated in endothelium of infarcted heart
We have explored the in vivo role of Pfn-1 phosphorylation in angiogenesis during tissue repair after myocardial infarction in which VEGF-A expression enhances and directs endothelial cell sprouting from capillaries, initiating angiogenesis, tissue growth and repair 6, 7, 42 . Robust angiogenesis was observed in infarcted cardiac tissue from human subjects, as indicated by an increased number of CD31 + vessels when compared with normal heart (Fig. 5a ). P-Pfn-1-Tyr-129 was similarly elevated in infarcted tissue, co-localizing almost exclusively with CD31 + blood vessels. In contrast, the distribution of Pfn-1 was uniformly expressed throughout cardiac tissue, as was the P-Akt-1-Ser-473 product of PI(3)K activation. Endothelial-cellspecific Pfn-1 phosphorylation was confirmed by co-localization with CD144 (VE-cadherin)-and VEGFR2-positive cells (Fig. 5b,c) . Quantitative immunofluorescence analysis of an array of normal and infarcted myocardium specimens showed Pfn-1 phosphorylation in infarcted tissue was 13-and 18-fold higher in acute myocardial infarction and scar-containing tissues, respectively, when compared with normal heart tissue ( Fig. 5d ). An even greater, 27-fold higher, level of Pfn-1 phosphorylation was observed in healing granulation tissue characterized by robust angiogenesis. These results reveal a remarkable, endothelial-cell-selective phosphorylation of Pfn-1 during cardiac tissue repair, and suggest a role for Pfn-1 phosphorylation in post-injury angiogenesis.
Pfn-1 phosphorylation at Tyr 129 is critical for VEGF-A-induced endothelial cell migration and post-injury angiogenesis in vivo
To rigorously test the role of Pfn-1 phosphorylation in angiogenesis in vivo, we generated conditional, endothelial-cellspecific, phosphorylation-deficient Pfn1 Y129F knock-in (Tie2-Cre; Pfn1 flox/flox:Y129F ) mice in the C57Bl/6 background. The mice have the terminal exon of the Pfn1 gene, which contains the phosphorylation site, flanked with LoxP sites followed by a minigene of the exon carrying a Y129F mutation (Fig. 6a) . The mice express Cre DNA recombinase under control of the endothelial-cell-specific Tie2 promoter 43, 44 . Endothelial-cell-specific knock-in by Tie2-directed Cre expression was verified by sequence analysis of Pfn1 messenger RNA from isolated endothelial cells and from de-endothelialized aorta in mice homozygous for the conditional null allele (Fig. 6a and Supplementary Fig. S6a ). Efficient expression of the mutant Y129F Pfn1 gene in knock-in mice was shown by near-complete abrogation of VEGF-inducible Pfn-1 phosphorylation at Tyr 129 in endothelial cells ( Fig. 6b and Supplementary Fig. S6b ). The Y129F mutation did not affect Pfn-1 mRNA or protein expression ( Fig. 6a and Supplementary  Fig. S6c ), and did not alter basal endothelial cell motility (Fig. 6c) or proliferation (Fig. 6d) . However, knock-in of Pfn1 Y129F / Y129F inhibited VEGF-A-stimulated planar migration of endothelial cells from mouse aorta, microvessel outgrowth in aortic ring explants, and endothelial cell chemotaxis, all by about 50% (Fig. 4c,e,f) . Inhibition of PI(3)K with the selective inhibitors LY294002 (10 µM) and wortmannin (0. 1 µM) also reduced migration of wild-type mouse endothelial cells by 50%, but endothelial cells) reduced chemotaxis to near the basal level (Fig. 6f) . Finally, expression of constitutively active RhoA Q63L and myr-Akt-1 did not rescue cell motility in Pfn1 Y129F / Y129F endothelial cells, consistent with the PI(3)K-independent role of Pfn-1 phosphorylation in VEGF-A-induced endothelial cell migration ( Supplementary Fig. S7 ). Unexpectedly, Pfn-1 phosphorylation did not interfere with developmental angiogenesis, as indicated by apparently normal embryos with unaffected microvessel density in the brain and heart at embryonic day E14.5, and intact retinal angiogenesis at postnatal day P5, in Pfn1 Y129F / Y129F knock-in mice (Fig. 7a) . However, endothelial cell knock-in of Pfn1 Y129F / Y129F substantially delayed wound closure after skin punch (Fig. 7b) , and significantly reduced the numbers of microvessels within the healing wounds and larger blood vessels in the region surrounding the injury (Fig. 7c) . In a separate model, angiogenesis after ischaemia induced by femoral artery ligation, as determined by microvessel density in hind limbs, was reduced by more than 50% in Pfn1 Y129F / Y129F knock-in mice (Fig. 7d) .
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Y129F / Y129F knock-in markedly suppressed blood flow recovery in the limbs (Fig. 7e) , suggesting another role of Pfn-1 phosphorylation in arteriogenesis, that is, collateral vessel formation. Likewise, angiography by micro-computed tomography (microCT) showed much less macrovessel growth in the ischaemic limb of Pfn1 Y129F / Y129F knock-in mice (Fig. 7f) . These results were confirmed in a distinct model in which Pfn1 Y129F / Y129F was expressed by tamoxifen-inducible, Cre-mediated recombination under the control of the endothelial-cell-specific Chd5 (VE-cadherin) promoter 45, 46 (Fig. 7g) , and similar reductions in blood flow recovery and microvessel density were observed (Fig. 7h,i) . Thus, Pfn-1 phosphorylation is required for post-ischaemia angiogenesis and arteriogenesis, in which endothelial cell migration and vessel sprouting play a critical role. Together, these findings reveal a critical role for Pfn-1 phosphorylation in pathological angiogenesis during tissue repair after injury, but not in physiological angiogenesis during development.
DISCUSSION
Eukaryotic cells respond to spatial heterogeneities in extracellular chemoattractants including VEGF by polarized activation of chemotactic receptors 47, 48 , asymmetric recruitment and activation of a branching, multistep pathway initiated by PI(3)K/Akt and PTEN, and consequent Rho GTPase-directed actin polymerization at the cell leading edge 47, 49, 50 . VEGF-inducible recruitment and activation of PI(3)K/Akt at the cell leading edge is thought to be particularly critical for endothelial cell polarization during chemotaxis 51 . However, abrogation of PI(3)K activity, including the main endothelial cell isoform, p110α, only partially inhibits VEGF-induced endothelial cell migration and vascular sprouting 51, 52 , suggesting that VEGFR might induce actin-based cell movement through an unidentified PI(3)K-independent pathway. Our results identify a PI(3)K-independent mechanism for regulating cell motility through stimulus-inducible phosphorylation of Pfn-1 at Tyr 129 and consequent increased interaction with G-actin. Dual activation of Pfn-1 phosphorylation and PI(3)K-mediated signalling are both required for maximal pro-migratory responses as suggested by the incomplete inhibition of endothelial cell migration observed when either PI(3)K activity or Pfn-1 phosphorylation is defective, but near-complete inhibition when both pathways are blocked. Furthermore, Pfn-1 phosphorylation by VEGFR2 and Src kinase bypasses classic multistep signalling events, thereby providing a more direct link between growth-factor-induced receptor activation and actin polymerization (Fig. 7j) . The intracellular signalling-independent short-cut by VEGFR2 phosphorylation of Pfn-1 might contribute to rapid initiation of cell polarity and determination of the migratory vector in response to extracellular VEGF stimulus. Activation of downstream tyrosine kinases, for example, Src, probably enhances and maintains Pfn-1 phosphorylation, especially after internalization and degradation of VEGFR kinases following ligand activation 34, 53 . Interestingly, although Pfn isoforms are present in all eukaryotes including yeast and plants, the appearance of the Tyr 129 phospho-site during evolution coincides with the appearance of vertebrates that exhibit closed circulatory systems, endothelial cell linings and VEGFR2, suggesting that stimulus-dependent regulation of Pfn activity is essential for blood vessel homeostasis (Supplementary Table S1 ).
Angiogenesis, initiated by directed endothelial cell migration, requires spatiotemporal regulation of cellular processes for which Pfn-1 phosphorylation may represent a critical control node. Pfn-1 phosphorylation stimulates the interaction between Pfn-1 and G-actin that is critical for endothelial cell motility and capillary morphogenesis 28 . Likewise, Pfn-1 phosphorylation contributes importantly to post-injury angiogenesis, as revealed by our conditional murine knock-in model. The robust expression of VEGFR2 in vascular endothelium probably contributes to highly selective Pfn-1 phosphorylation in endothelial cells. In contrast, PI(3)K is required for developmental and pathological angiogenesis 54, 55 , and knockout of p110α, the main PI(3)K isoform in endothelial cells, partially inhibits cell motility but causes embryonic lethality in mice 51 , consistent with the widespread role of PI(3)K in cell growth, proliferation, survival and motility in multiple cell types [56] [57] [58] . The fractional contribution of Pfn-1 phosphorylation to VEGF-induced endothelial cell motility and vessel sprouting might complement PI(3)K-mediated signals to induce maximal angiogenesis, particularly during pathological states. In summary, our results reveal a previously unidentified regulatory system for endothelial cell migration and angiogenesis. Its endothelial-cell-preferential induction in infarcted heart, but dispensability in development, suggest that Pfn-1 phosphorylation may present a highly selective and non-noxious target for therapeutic intervention of pathological angiogenesis.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary Information is available in the online version of the paper
METHODS
Cell culture. Bovine aortic endothelial cells were isolated and cultured as described previously 19 . Human umbilical vein and microvascular endothelial cells were maintained in endothelial cell growth medium with SingleQuots supplements (Lonsa). Mouse aortic endothelial cells were cultured in DME/Ham's F-12 medium (Invitrogen) supplemented with 25 µg ml −1 endothelial cell growth supplement (Sigma), 10 U ml −1 heparin and fetal bovine serum (FBS). Human heart fibroblasts were cultured in DMEM medium supplemented with 10% FBS.
Plasmids, siRNAs and transfection. The Pfn1 CDS was amplified from a bovine cDNA pool (BioChain) and subcloned into pcDNA 3.1 (Invitrogen) with Flagtag. Human Pfn1 cDNA (OriGene) was subcloned into pECFP (Clontech) and pTriEx (Novagen) with His-tag. Cloned plasmids were verified by sequencing. pEZ-VEGFR1-HA/His was from GeneCopoeia, and pCMV6-VEGFR2-Myc was from Origene. Endothelial cells were transfected with plasmids using Fugene HD (Roche) in serum-free Opti-MEM medium (Invitrogen). Endothelial cells were transfected with pre-made SMART pool siRNA targeting VEGFR1 (Millipore L003136), VEGFR2 (Millipore L003148), p110-α (Millipore L003018), -β (Millipore L003019), -δ (Millipore L006775) and -γ (Millipore L005274), or Src (Santa Cruz SC29228), Fyn (Santa Cruz SC29321), Lyn (Santa Cruz SC29393), FAK (Santa Cruz SC29310) and Luc siRNA (Invitrogen 12935-146) using Lipofectamine 2000 (Invitrogen).
Mutagenesis. Pfn-1, VEGFR2 and RhoA mutants were generated by PCR using the GeneTailor Site-Directed Mutagenesis System (Invitrogen). pcDNA-Pfn-1-Flag and pTriEx-Pfn-1-His were used as a template to generate Y129A and Y129F mutations, and pCMV6-VEGFR2-Myc was used to generate Y951F, Y1175F and Y1214F mutations. pGEX-GST-RhoA was used as a template to generate Q63L mutation, and RhoA mutant was subcloned into pTriEx. All clones were verified by sequencing.
Immunoprecipitation, immunodepletion and immunoblot analysis. Immunoprecipitation and immunoblotting were performed as described previously 19 . In brief, cell lysates were pre-cleared with agarose-conjugated IgG (Santa Cruz), and then incubated with agarose-conjugated Flag antibody (M2, 1:100, Sigma F2426) or anti-Pfn-1 antibody (1:50, Cell Signaling 3237), followed by incubation with agarose-conjugated protein A/G (1:30, Santa Cruz). For immunodepletion, cell lysates were incubated with anti-Flk-1 (1:30, Santa Cruz SC504), anti-Src (1:30, Cell Signaling 2108) or control IgG, followed by incubation with agarose-conjugated protein A/G (1:50, Santa Cruz). Proteins were resolved by SDS-PAGE, and blotted with anti-β-actin (1:2,000, Cell Signaling 4970), anti-P-Tyr (1:500, CalBiochem S25322), anti-P-Ser (1:500, BioDesign K67560M), anti-P-Thr (1:500, BioDesign K67600M), anti-Flag (M2, 1:1,000, Sigma F1804) or anti-Pfn-1 (1:1,000, Cell Signaling 3237) antibodies. Proteins were detected with HRP-conjugated conformation-specific antibody that do not recognize IgG heavy and light chains (Pierce).
Mass spectrometric analysis of Pfn-1 phosphorylation. Human endothelial cells were transfected with pTriEx-Pfn-1-His, and cell lysates were precipitated with Ni + particles (Pierce). Proteins were resolved by SDS-PAGE and stained with GelCode blue (Pierce). The Pfn-1 band was excised, in-gel digested with trypsin, and subjected to capillary column liquid chromatography-tandem mass spectrometry analysis as described previously 59 .
Generation of Pfn-1 phospho-specific antibody. Polyclonal, phospho-specific antibody against the Pfn-1 P-Tyr-129 site was generated by injection of synthetic KLH-conjugated peptide, KKCpYEMASHLRR, into rabbits (Open Biosystems). The serum was affinity-purified using the same peptide, and non-phospho-specific antibody was depleted by affinity purification using peptide containing unmodified tyrosine.
Metabolic labelling. Confluent, quiescent or subconfluent, migrating bovine aortic endothelial cells were treated with human VEGF-A (10 ng ml −1 , R&D Systems) for 4 h and then labelled with [ 32 P]orthophosphate (500 µCi, Perkin-Elmer) for 4 h in phosphate-free medium.
32 P-labelled cells were lysed in PhosphoSafe buffer (Novagen), and labelled proteins were immunoprecipitated with anti-Pfn-1 antibody (1:50, Cell Signaling 3237). Proteins in immunoprecipitates were resolved by SDS-PAGE, and bands were visualized by autoradiography.
Protein expression and purification. pTriEx-Pfn-1-His and pTriEx-thymosin-β4-His were transformed into the Tuner lacZY deletion mutant of BL21 bacteria (Novagen), and protein expression was induced with 0.1 mM IPTG (Invitrogen) at 30 • C for 5 h. Soluble protein was extracted with CellLytic B cell lysis reagent (Sigma), and Pfn-1-His and thymosin-β4-His were purified with B-PER His purification kit (Pierce).
In vitro phosphorylation. Cell lysates (0.5 µg) were incubated with purified recombinant His-or GST-tagged cytoplasmic domains of VEGFR1, VEGFR2 and VEGFR3, and FAK (25 ng, Cell Signaling) and His-tagged human Pfn-1 (1 µg, Cytoskeleton) for in vitro phosphorylation assay as described previously 59 .
Surface plasmon resonance. His-tagged Pfn-1 (100 µg) was incubated with cell lysate (50 µg) for 15 min in kinase assay buffer. Pfn-1 was purified with a MagneHis Ni + -particle Purification System (Promega), washed twice with a buffer of 10 mM Tris at pH 7.4, 1 M NaCl, 10 mM dithiothreitol and 1% Triton X-100 to remove Pfn-1-interacting proteins, and dialysed in BIAcore running buffer. Purified β-actin (Cytoskeleton) was immobilized on a CM5 sensor chip (GE health). Binding was measured using a BIAcore 3000 instrument as described previously 19 .
Nucleotide-exchange measurement. The rate of nucleotide exchange on Gactin was measured by monitoring the fluorescence intensity increase in G-actin binding to ε ATP (1, N 6-ethenoadenosine 5 -triphosphate, Invitrogen) as described previously 60 .
Lipid co-sedimentation assay. PtdIns(4,5)P 2 binding to Pfn-1 was assessed by co-sedimentation with small, unilamellar vesicles as described previously 61 .
Lipid filtration assay. PtdIns(4,5)P 2 binding to Pfn-1 was determined with a filter assay as described previously 62 .
Actin polymerization assay. Actin (Cytoskeleton, 2 µM, with 10% pyrenel actin) was induced to polymerize by the addition of MgCl 2 (2 mM) and spectrin-actin seeds (30 ng ml −1 ) in G-buffer with or without Pfn-1 and thymosin-β4 as described previously 25 .
Immunocomplex kinase assay. Cell lysate (500 µg) was incubated with antibody
(1:50) against VEGFR2 (Santa Cruz SC504) or Src (Cell Signaling 2108), or control IgG. The immunocomplex was captured with protein A-Sepharose beads (Sigma), washed, suspended in kinase assay buffer and incubated with purified human Pfn-1 (0.1 µg, Cytoskeleton) for in vitro phosphorylation assay as described previously 59 .
Transwell chemotaxis assay. Mouse aortic endothelial cells were seeded on
Transwell inserts with an 8-µm pore filter (Costar). Cell migration was induced by mouse VEGF-A (R&D systems), and analysed as described previously 19 . Retrovirus-based expression. Phoenix-Ampho packaging cells were transfected with pWZL-neo-myr-Akt1 or empty vector (Cell Biolabs) using Fugene HD transfection reagent (Roche). Virus-containing medium was collected 48 h after transfection and used immediately. Endothelial cells were infected at a density of 1 × 10 6 cells ml −1 in the presence of 8 µg ml −1 Polybrene, overnight.
Chemotaxis assay in a Zigmond
Immunofluorescence analysis of tissue sections. Human cardiac autopsy specimens from healthy controls or subjects with myocardial infarction (BioChain, US Biomax and BioCat) were de-paraffinized and rehydrated, and subjected to antigen retrieval in Target intensity was quantified by using NIH ImageJ software. Co-localization analysis was performed by using ImagePro software.
Generation of conditional Pfn1 Y129F knock-in mice. Knock-in mice carrying a Pfn1 Y129F mutation (Pfn1 flox/flox:Y129F ) were generated in the C57B1/6T background (Taconic). In brief, a Pfn1 minigene (Fig. 6a) bearing the Y129F mutation in exon 3 downstream of LoxP-flanked, wild-type terminal exon 3 was subcloned into pCR4.0 vector with an FRT -flanked neomycin-resistance cassette, and electroporated into mouse embryonic stem cells. Cells expressing the mutant allele were selected with neomycin, identified by PCR and verified by Southern blotting, and subjected to Flp-mediated excision of the neomycin resistance cassette. Positive colonies were injected into fertilized mouse blastocysts and chimaeras were bred to generate heterozygous Pfn1 Tails of E14.5 embryos and pups were genotyped by PCR using the following forward (FP) and reverse (RP) primer pairs: Pfn-1 FP, 5 -GAGATTAGTTTGCTTAGGGCAGTTGGG-3 ; Pfn-1 RP, 5 -GGCTGTCAGTCAT-CCTAAAACAATAGAGC-3 ; Tie2 FP, 5 -GCGGTCTGGCAGTAAAAACTATC-3 ; Tie2 RP, 5 -GTGAAACAGCATTGCTGTCACTT-3 ; internal positive control FP for Tie2, 5 -CTAGGCCACAGAATTGAAAGATCT-3 ; internal positive control RP for Tie2, 5 -GTAGGTGGAAATTCTAGCATCATCC-3 ; Cdh5 FP, 5 -CTGGGATGCTGAAGGCATCAC-3 ; Cdh5 RP, 5 -TTGCGAACCTCATCACTCG-TT-3 .
All animal protocols were approved by the Animal Research Committee of the Cleveland Clinic, and all animals were housed in the Association for the Assessment and Accreditation of Laboratory Animal Care-accredited animal facility of the Cleveland Clinic. Equal numbers of male and female mice were used.
Aortic endothelial cell sprouting assay. Thoracic aortae were isolated from mice (2 weeks old), and aortic rings were placed on dishes pre-coated with growth factor-reduced Matrigel (BD Biosciences). After 20 min at 37 • C, the surface was washed three times with PBS. Rings were incubated in serum-free medium containing 2% BSA and 10 ng ml −1 mouse VEGF-A for three days, and imaged using a DM-IRB inverted microscope (Leica). Aortic endothelial cells were isolated as described previously 63 .
RT-PCR and sequence analysis. The endothelial layers of mouse aortae were removed by razor scraping. mRNA was isolated from endothelial cells and from the remaining de-endothelialized aorta with a RNeasy kit (Qiagen), and subjected to reverse transcription-PCR with an AgPath-ID One-Step RT-PCR kit (Ambion). The following primers were used, for β-actin FP, 5 -ACTGGAACGGTGAAGGTGAC-3 ; β-actin RP, 5 -TGATGGCTGTCCATTCAAAA-3 (β-actin nucleotides 1368-1694, product = 327 bp); Pfn-1 FP, 5 -ATGGCCGGGTGGAACGC-3 ; Pfn-1 RP, 5 -TCAGTACTGGGAACGCCGCA-3 (full-length mouse Pfn1 CDS, product = 423 bp).
Cell proliferation assay. Mouse aortic endothelial cells were seeded on 96-well plates and cultured with 5% FBS. Cells were washed with 100 µl fresh medium and incubated with methylthiazolyldiphenyl-tetrazolium bromide (MTT, 10 µl of 12 µM) for 4 h at 37 • C. After adding 100 µl of 10% SDS in 10 mM HCl, absorbance was measured at 570 nm with a reference at 620 nm in a Spectramax 190 spectrophotometer (Molecular Devices).
Wound-induced cell migration. Mouse aortic endothelial cells were induced to migrate as described previously 64 .
Mouse retina analysis. Mouse eyes at postnatal P5 were dissected and stained as previously described 9 .
Punch wound. Mice (about 6 weeks old) were anaesthetized by intraperitoneal injection of xylazine (10 mg kg −1 ) and ketamine (100 mg kg −1 ). Skin wounds on the backs were induced with a 3-mm biopsy punch (Premier) as described previously 65 .
Hindlimb ischaemia model. Under a stereomicroscope, the right superficial femoral artery of anaesthetized mice (about 8 weeks old) was ligated proximal to the caudally branching deep femoral artery, and a second ligation was made just proximal to the branching of the tibial arteries. The artery was excised between the ligation points, leaving the vein and femoral nerve intact. The skin was closed, and the mice were allowed to recover for four weeks.
Laser Doppler imaging. Laser Doppler imaging was performed before and 7, 14 and 21 days after surgery to assess blood flow perfusion in the ischaemic hindlimb. Anaesthetized mice were scanned with a Doppler system (moorLDI2-IR near-infrared laser Class 3R, Moor Instruments) and results are plotted as a ratio of the operated leg to the contralateral control leg (perfusion units) for each animal.
Angiography by microCT. Mice were euthanized and sequentially perfused at physiological pressure using normal saline with 100 U ml −1 heparin (Sigma), 10% neutral-buffered formalin, and again with saline. The vascular system was injected with a lead-chromate-based polymerizing contrast agent (Microfill MV-122, Flow Tech). Specimens were incubated with decalcification solution (Cal-Ex II, Fisher) at 4 • C for 2 weeks. The ischaemic legs were imaged with an eXplore Locus microCT instrument (GE Healthcare), and tomograms were used to render three-dimensional images with customized software (Image-IQ).
Statistical analysis. Student's t -test (OriginLab) was used for statistical analysis between groups with P < 0.05 representing a statistically significant difference. . This spectrum contains a N-terminal carbamidomethylated Cys residue which has lost a mass of 17 Da. This modification is due to cyclization of the N-terminal Cys residue and is believed to occur after digestion. In addition, the spectra contains several sequence ions including y 7 and y 8 whose mass difference is consistent with the presence of a pTyr residue at position 129. 5% 10% 15%
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